166 results on '"Friedhoff, Lawrence"'
Search Results
2. Lost interest for existing compounds: New boosts
3. A call for a global ‘bigger’ data approach to Alzheimer disease
4. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities
5. Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability
6. Comparative Pharmacokinetics of Lovastatin Extended-Release Tablets and Lovastatin Immediate-Release Tablets in Humans
7. Donepezil Improves Cognition and Global Function in Alzheimer Disease: A 15-Week, Double-blind, Placebo-Controlled Study
8. A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin
9. A call for a global ‘bigger’ data approach to Alzheimer disease
10. EVALUATION OF THE NEUROPROTECTIVE EFFECT OF INTEPIRDINE IN AN IN VITRO OXYGEN/GLUCOSE DEPRIVATION-INDUCED CYTOTOXICITY MODEL
11. HEADWAY-DLB: A MULTINATIONAL STUDY EVALUATING THE SAFETY AND EFFICACY OF INTEPIRDINE (RVT-101) IN DEMENTIA WITH LEWY BODIES
12. [P2-007]: A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF COMBINATIONS OF DONEPEZIL WITH GLYCOPYRROLATE OR TROSPIUM IN ELDERLY VOLUNTEERS: THE RVT-103 PROGRAM
13. RESULTS OF A PHASE 2 STUDY OF NELOTANSERIN, A NOVEL 5HT2A RECEPTOR INVERSE AGONIST, IN LEWY BODY DEMENTIA SUBJECTS EXPERIENCING VISUAL HALLUCINATIONS
14. A SUMMARY OF BASELINE EFFICACY CHARACTERISTICS FROM THE MINDSET STUDY: A GLOBAL PHASE 3 STUDY OF INTEPIRDINE (RVT-101) IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
15. TRANSLATING BENCH RESEARCH INTO EVOLVING DRUG DEVELOPMENT: THE CASE STUDY OF 5HT6 ANTAGONISTS
16. A Phase 2 Study of Nelotanserin, a Novel 5HT2A Receptor Inverse Agonist, in Dementia with Lewy Bodies and Parkinson’s Disease Dementia Subjects Experiencing Visual Hallucinations (P6.088)
17. An Assessment of Dependence in Dementia Using A Conversion Algorithm of ADCS-ADL to Dependence Scale From a Double Blind Placebo Controlled Trial of Intepirdine (RVT-101) (P3.088)
18. Intepirdine (RVT-101), a 5-HT6 Receptor Antagonist, as an Adjunct to Donepezil in Mild-to-Moderate Alzheimer's Disease: Efficacy on Activities of Daily Living Domains
19. Examining the Clinical Profile of Nelotanserin, a Novel Agent in Development for Lewy Body Dementia
20. Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19
21. Evaluation of Noribogaine Safety, Pharmacokinetics and Effects on Opioid Withdrawal in Methadone-Dependent Patients
22. P4-001: A Large, Randomized, Double-Blind, Placebo-Controlled Study Evaluating RVT-101, A Neurotransmitter-Targeted Therapy, in Subjects with Mild-to-Moderate Alzheimer's Disease on Donepezil Treatment: Phase 3 Mindset Study Design
23. P4-022: IN VIVO Alterations in Brain Glucose Utilization with RVT-101, a 5Ht6 Inhibitor for the Treatment of Alzheimer’s Disease
24. P3-018: An Evaluation of the Safety of Nelotanserin, A Highly Potent and Selective 5-HT2A Inverse Agonist That is Being Developed as a Treatment for Visual Hallucinations and REM Behavior Disorder in Lewy Body Dementia
25. P3-014: Effect of Food on the Pharmacokinetics Of RVT-101 in Healthy Adult Subjects
26. Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients
27. Switching Opioid-Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics
28. Targeting the seed and the soil of cancers with selective small-molecule inhibitors of CDK8/19: Chemopotentiating, chemopreventive, anti-invasive and anti-metastatic activities
29. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities
30. DT-01-04: The efficacy of RVT-101, a 5-ht6 receptor antagonist, as an adjunct to donepezil in adults with mild-to-moderate Alzheimer's disease: Completer analysis of a phase 2b study
31. P4-302: RVT-101, a 5-ht6 receptor antagonist, as adjunctive therapy with donepezil in adults with mild-to-moderate Alzheimer's disease: Responder analysis
32. A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF COMBINATIONS OF DONEPEZIL WITH GLYCOPYRROLATE OR TROSPIUM IN ELDERLY VOLUNTEERS: THE RVT-103 PROGRAM
33. Poster Number: NR 15 - Examining the Clinical Profile of Nelotanserin, a Novel Agent in Development for Lewy Body Dementia
34. Poster Number: NR 5 - Intepirdine (RVT-101), a 5-HT6 Receptor Antagonist, as an Adjunct to Donepezil in Mild-to-Moderate Alzheimer's Disease: Efficacy on Activities of Daily Living Domains
35. Abstract PR08: Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19
36. Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability
37. Abstract 4879: Targeting the seed and the soil of cancers with selective small-molecule inhibitors of CDK8/19: Chemopotentiating, chemopreventive, anti-invasive and anti-metastatic activities
38. IN VIVO ALTERATIONS IN BRAIN GLUCOSE UTILIZATION WITH RVT-101, A 5HT6 INHIBITOR FOR THE TREATMENT OF ALZHEIMER’S DISEASE
39. A LARGE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING RVT-101, A NEUROTRANSMITTER-TARGETED THERAPY, IN SUBJECTS WITH MILD-TO-MODERATE ALZHEIMER’S DISEASE ON DONEPEZIL TREATMENT: PHASE 3 MINDSET STUDY DESIGN
40. EFFECT OF FOOD ON THE PHARMACOKINETICS OF RVT-101 IN HEALTHY ADULT SUBJECTS
41. AN EVALUATION OF THE SAFETY OF NELOTANSERIN, A HIGHLY POTENT AND SELECTIVE 5-HT2A INVERSE AGONIST THAT IS BEING DEVELOPED AS A TREATMENT FOR VISUAL HALLUCINATIONS AND REM BEHAVIOR DISORDER IN LEWY BODY DEMENTIA
42. Abstract 1820: CDK3: A novel tumor-selective drug target involved in AP1 activation and transcriptional damage response
43. Phenserine Efficacy in Alzheimer's Disease
44. The efficacy of RVT-101, a 5-ht6 receptor antagonist, as an adjunct to donepezil in adults with mild-to-moderate Alzheimer’s disease: Completer analysis of a phase 2b study
45. RVT-101, a 5-ht6 receptor antagonist, as adjunctive therapy with donepezil in adults with mild-to-moderate Alzheimer’s disease: Responder analysis
46. P2-417: Oral phenserine tartrate treatment is associated with reduced plasma Abeta 1-42 in a phase I clinical study
47. P1-004: Oral treatment of mice with Posiphen™ significantly lowers brain levels of beta amyloid (1-42)
48. P3–459: Double–blind placebo–controlled evaluation of the safety and efficacy of phenserine tartrate (PT) for the treatment of mild to moderate Alzheimer's disease (AD)
49. Pharmacokinetics and dose proportionality of extended‐release metformin following administration of 1000, 1500, 2000 and 2500 mg in healthy volunteers
50. Pharmacokinetics of lovastatin extended‐release dosage form (Lovastatin XL) in healthy volunteers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.